Jade Biosciences (JBIO) Stock Price, News & Analysis

Company Overview

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Key Stats

• Today's Range: $9.10 to $10.82
• 50-Day Range: N/A
• 52-Week Range: $6.57 to $105.00
• Volume: 243,176 shs
• Average Volume: 477,362 shs
• Market Capitalization: $7.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.00
• Consensus Rating: Buy

Jade Biosciences Stock Analysis - MarketRank™

Jade Biosciences scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Jade Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Jade Biosciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Jade Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jade Biosciences is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jade Biosciences has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for JBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jade Biosciences does not currently pay a dividend.

Dividend Growth

Jade Biosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for JBIO.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.94

News Sentiment

Jade Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Jade Biosciences this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for JBIO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

MarketBeat Follows

1 people have added Jade Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jade Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.90% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

JBIO Stock Analysis - Frequently Asked Questions

How have JBIO shares performed this year?

Jade Biosciences' stock was trading at $7.06 at the beginning of 2025. Since then, JBIO shares have increased by 31.0% and is now trading at $9.25.
View the best growth stocks for 2025 here.

How do I buy shares of Jade Biosciences?

Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 6/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JBIO
• CIK: 1798749
• Web: N/A
• Phone: (617) 443-2400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $14.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +51.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($59.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.63 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -60.01%
• Return on Assets: -54.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 32.01
• Quick Ratio: 32.01

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $92.88 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 840,000
• Free Float: 632,000
• Market Cap: $7.77 million
• Optionable: N/A
• Beta: 0.93